DevelopmentFeb 20, 2023In this webinar in collaboration with Contract Pharma, Jina Kim, our Senior Scientist at our Bio R&D Center, shares insights about new approaches in bispecific antibody development while introduciSamsung BIO Insight삼성바이오로직스 경쟁력 집중탐구: 이중항체가 궁금해Nov 29, 2022 생명공학 기술의 발전으로 글로벌 의약품 시장 중심축은 합성의약품에서 바이오의약품으로 이동하고 있습니다. 바이오의약품 중 가장 높은 점유율을 차지하고 있는 것은 ‘항체치료제’인데요, 1986년 최초의 단일클론항체 치료제가 미국 FDA 승인을 획득한 이후 항체 제작 기술도 비약적으로 발전해왔습니다. 기존 단일항체 대비 효능을 개선한 차세대 항체가 속속 등장하PostersSamsung Biologics Developability Assessment Plaform: DEVELOPICK™ for Rapid and Accurate Evaluation of Thermal and Chemical StabilitySep 16, 2022 PostersEfficient Management of Downstream Process Characterization at Samsung BiologicsSep 16, 2022 WhitepapersFundamental Considerations for Bispecific Antibody-based Cell Line DevelopmentJun 21, 2022 WHITE PAPER Fundamental Considerations for Bispecific Antibody-based Cell Line Development Seahee Kim Head of Cell Line Development The innovative dual specificity ofPostersSamsung Biologics Bispecific Antibody PlatformMay 26, 2022 Bispecific Antibody Platform A Novel Asymmetrical Structure for Therapeutic Antibodies An emerging class of next-generation antibody therapy, bispecific antibWebinarsAccelerated High-performing Platform Process of Monoclonal Antibody: Upstream Optimization Case StudyMay 17, 2021Selecting the right CDMO partner is critical for any institution as the decision can impact product quality, cost and timeline. This presentation will delve into the CDO Upstream Process at Samsung BiWebinarsWhat to consider in selecting the best cell line to accelerate the timeline to INDApr 19, 2021The start of a biologic’s developmental journey is represented with cell line development. During this exciting milestone, a suitable cell line must be selected for optimizing the remaining processes Samsung BIO Insight삼성바이오로직스 경쟁력 집중탐구: 바이오의약품 위탁개발(CDO)이 궁금해Aug 31, 2021 세계 최대 규모의 바이오의약품 생산기지인 삼성바이오로직스는 위탁생산(CMO)뿐 아니라 위탁개발(CDO)까지 사업 영역을 확장하며 원스톱 CDMO로서 글로벌 시장을 선점해 나가고 있는데요, 2020년 10월에는 미국의 대표 바이오 클러스터인 샌프란시스코에 R&D센터를 개소하며 고객사와의 물리적 거리를 좁히고, 신속한 서비스를 제공하는 ‘넥스트 도어(Samsung BIO InsightExploring Samsung Biologics’ CDO capabilities | Bispecific antibodiesNov 29, 2022Driven by advances in biotechnology, biopharmaceuticals are among the most sophisticated achievements of modern science ...WebinarsNew Approaches in Bispecific Antibody DevelopmentFeb 20, 2023In this webinar in collaboration with Contract Pharma, Jina Kim, our Senior Scientist at our Bio R&D Center, shares insights about new ...WebinarsNew Approaches in Bispecific Antibody DevelopmentFeb 20, 2023In this webinar in collaboration with Contract Pharma, Jina Kim, our Senior Scientist at our Bio R&D Center, shares insights about new ...Samsung BIO InsightExploring Samsung Biologics’ CDO capabilities | Bispecific antibodiesNov 29, 2022Driven by advances in biotechnology, biopharmaceuticals are among the most sophisticated achievements of modern science ...WebinarsNew Approaches in Bispecific Antibody DevelopmentFeb 20, 2023In this webinar in collaboration with Contract Pharma, Jina Kim, our Senior Scientist at our Bio R&D Center, shares insights about new ...WebinarsNew Approaches in Bispecific Antibody DevelopmentFeb 20, 2023In this webinar in collaboration with Contract Pharma, Jina Kim, our Senior Scientist at our Bio R&D Center, shares insights about new ...Samsung BIO InsightExploring Samsung Biologics’ CDO capabilities | Bispecific antibodiesNov 29, 2022Driven by advances in biotechnology, biopharmaceuticals are among the most sophisticated achievements of modern science ...WebinarsNew Approaches in Bispecific Antibody DevelopmentFeb 20, 2023In this webinar in collaboration with Contract Pharma, Jina Kim, our Senior Scientist at our Bio R&D Center, shares insights about new ...WebinarsNew Approaches in Bispecific Antibody DevelopmentFeb 20, 2023In this webinar in collaboration with Contract Pharma, Jina Kim, our Senior Scien